In the subgroup analysis of the KEYNOTE-189 trial, the overall response rate (ORR) of pembrolizumab in combination with platinum plus pemetrexed was 30.6% in NSCLC patients with STK11 mutation, whereas it was 48.8% in those with STK11 wild type (67) (Supplementary Table 2). Here, STK11 is linked to non-small cell lung carcinoma.